Wiley Bros. Aintree Capital, LLC Ionis Pharmaceuticals Inc Transaction History
Wiley Bros. Aintree Capital, LLC
- $8.04 Billion
- Q4 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 10,317 shares of IONS stock, worth $327,667. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,317
Previous 9,606
7.4%
Holding current value
$327,667
Previous $384,000
6.25%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding IONS
# of Institutions
412Shares Held
140MCall Options Held
829KPut Options Held
789K-
Vanguard Group Inc Valley Forge, PA16.5MShares$523 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.2MShares$450 Million0.31% of portfolio
-
Capital World Investors Los Angeles, CA11.5MShares$364 Million0.06% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$328 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.67MShares$275 Million0.06% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $4.51B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...